Estrogenic and Progestogenic Activity of Testosterone Enanthate
Testosterone enanthate is often described simply as an androgen, but part of what it does in the body happens after conversion into other hormones. Estradiol, produced from testosterone by the enzyme aromatase, drives several of the effects people associate with testosterone therapy, both wanted and unwanted. Our editorial team explains the chemistry, the clinical picture and what doctors monitor.
From ester to active hormone
Testosterone enanthate is an ester: testosterone joined to heptanoic acid. The ester makes the molecule more lipophilic, so after an intramuscular injection it leaves the oil depot slowly. Blood esterases cleave the ester, releasing testosterone identical to the hormone produced by the testes.
From that point, three main routes matter. Testosterone can act directly on the androgen receptor; it can be reduced by 5-alpha reductase to dihydrotestosterone (DHT), a more potent androgen; or it can be converted by aromatase to estradiol, the principal estrogen.
Aromatase is found in adipose tissue, liver, brain, bone and other tissues. Because fat tissue is a major site, people with more body fat generally convert a larger share of testosterone to estradiol.
This conversion is physiological and necessary. Estradiol in men contributes to bone mineral density, lipid metabolism, libido and brain function, as demonstrated in work by Finkelstein et al. (2013), who separated the roles of testosterone and estradiol experimentally.
Why estradiol matters in men
Finkelstein's study in the New England Journal of Medicine suppressed endogenous hormone production and gave graded testosterone doses with or without an aromatase inhibitor. Lean mass and strength tracked testosterone, while fat accumulation and sexual desire were influenced substantially by estradiol.
That finding reframed a common assumption. Estradiol is not simply a side effect to be eliminated; too little is associated with low libido, joint discomfort and adverse bone effects.
Too much estradiol, however, produces recognizable problems. Gynecomastia, breast tenderness, fluid retention, mood changes and reduced libido are reported when levels rise well above the normal male range.
In clinical practice, estradiol is interpreted together with symptoms. The Endocrine Society guideline on testosterone therapy (Bhasin et al., 2018) focuses monitoring on testosterone levels, hematocrit, prostate-specific antigen where applicable and symptom response rather than on routine aromatase blocking.
What progestogenic activity means
Progestogenic activity refers to a steroid's ability to activate the progesterone receptor. This property is prominent in 19-nortestosterone compounds such as nandrolone and in some synthetic progestins used in contraception.
Testosterone itself has minimal affinity for the progesterone receptor at physiological concentrations. For that reason, testosterone enanthate is not usually described as a progestogenic drug.
Why does the question keep coming up? Because the clinical signs often blamed on "progesterone" in gym discussions, such as nipple sensitivity or fluid retention, overlap with estrogen-related effects. Attribution based on symptoms alone is unreliable.
Prolactin adds to the confusion. Elevated prolactin can cause breast tenderness and sexual dysfunction and has been reported with certain anabolic steroid use patterns. Prolactin is regulated separately and requires its own blood test.
| Receptor pathway | Testosterone enanthate | Typical clinical association |
|---|---|---|
| Androgen receptor | Primary action, direct and via DHT | Muscle, libido, skin, hair |
| Estrogen receptor (via estradiol) | Significant, dose-dependent | Breast tissue, water retention, bone, mood |
| Progesterone receptor | Minimal | Prominent for 19-nor compounds, not testosterone |
Signs, symptoms and monitoring
Clinicians look at a combination of symptoms and laboratory data. Breast tenderness or a firm, tender lump under the nipple is the classic presentation of gynecomastia and should be examined by a physician, since other causes exist, including rare breast cancer in men.
- Estradiol: ideally measured with a sensitive (mass spectrometry) assay in men, since standard immunoassays perform poorly at low concentrations.
- Total testosterone: interpreted relative to the timing of the last dose during therapy.
- Hematocrit and hemoglobin: androgen therapy can raise red cell mass.
- Blood pressure: fluid retention and androgen effects can raise it.
- Prolactin: when breast symptoms or sexual dysfunction are unexplained.
- Lipid panel: androgens can lower HDL cholesterol.
Rising weight with puffiness in the face and ankles may point to fluid retention. This is one reason blood pressure deserves monitoring rather than guesswork.
A key practical point: the relationship between dose, estradiol and symptoms varies considerably between individuals, driven by body composition, genetics and aromatase activity.
Why self-managed estrogen control goes wrong
Online culture treats aromatase inhibitors as routine companions to testosterone. The medical reality is different: inhibitors such as anastrozole are approved for breast cancer in women, and their use in men is off-label and not recommended as standard practice alongside testosterone therapy.
Crushing estradiol has consequences. Low estradiol in men has been associated with reduced bone mineral density, joint pain, low libido and worsened lipid profiles. Some men who chase a target number end up feeling worse than before.
Non-medical users often add inhibitors preemptively, without measuring estradiol, using insensitive assays, or interpreting symptoms that may have other causes. This is guesswork with a hormone that influences bone and cardiovascular health.
We do not publish dosing protocols for these drugs. The appropriate route for anyone with breast tenderness, swelling or mood changes during testosterone therapy is an evaluation by the prescribing physician, who can measure the relevant hormones and adjust treatment.
For men using testosterone without a prescription, the same symptoms are still a reason to see a clinician. Honest disclosure allows proper testing, and medical confidentiality protects the discussion.
Conclusions of the editorial team
Testosterone enanthate acts through the androgen receptor, through DHT and, importantly, through conversion to estradiol by aromatase.
Estradiol is required for bone, lipid, libido and brain health in men; both excess and deficiency cause problems, so the goal is balance, not elimination.
Testosterone has minimal progestogenic activity; symptoms often attributed to progesterone usually reflect estrogen effects or elevated prolactin and need proper testing.
Self-managed aromatase inhibition is a common source of harm and should be replaced by physician-guided monitoring. See also our articles on gynecomastia evaluation, sensitive estradiol testing, and hematocrit monitoring during testosterone therapy.
References
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–1022.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol. 2009;5(10):559–568.
- Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an Endocrine Society position statement. J Clin Endocrinol Metab. 2013;98(4):1376–1387.
- Nieschlag E, Behre HM, Nieschlag S, eds. Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012.
- Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
